Trending...
- Rx Processing Corp.com The Forth Of July 2025
- From Real Estate to Reel Power: H.L Woods Carves His Legacy as a Cutting-Edge Visionary Filmmaker
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
BOSTON, May 20, 2024 ~ Chroma Medicine, Inc. has recently announced the appointment of Jenny Marlowe, Ph.D., as their new Chief Development Officer. Dr. Marlowe brings with her a wealth of experience and expertise in the field of genomic medicine, making her a valuable addition to the company's leadership team.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
According to Catherine Stehman-Breen, M.D., CEO of Chroma, the company is thrilled to have Dr. Marlowe on board during this crucial time as they prepare to transition to clinical trials. Her leadership and knowledge will be instrumental in bringing their innovative epigenetic editing therapies to patients.
Prior to joining Chroma, Dr. Marlowe served as the Chief Scientific Officer at Solid Biosciences (previously AvantiBio), where she led discovery, research, and translational development. She also held the position of Vice President of Preclinical and Translational Development at bluebird bio, where she played a key role in the development of Zynteglo, a gene therapy for beta thalassemia that has since been approved.
More on Ohio Pen
- Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
- AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
- Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
- Civista Bancshares, Inc. Announces Agreement to Acquire The Farmers Savings Bank; Launches Public Offering of Common Shares
Dr. Marlowe's career began at Novartis, where she held various leadership positions including Global Head of Strategic Planning and Communication and Director of Translational Safety Models in Preclinical Safety. She holds a Ph.D. in Molecular Toxicology from the University of Cincinnati and a B.S. in Zoology from Miami University.
In her new role at Chroma, Dr. Marlowe will be focusing on advancing their epigenetic editing platform which utilizes the cell's natural system to regulate gene expression without altering DNA. This technology has shown great potential for creating groundbreaking medicines.
Expressing her excitement about joining Chroma, Dr. Marlowe stated that their epigenetic editing platform is an incredibly compelling technology for developing transformative medicines. She is eager to work with the team at Chroma and help bring this new class of genomic therapies to patients.
With Dr. Marlowe's extensive experience and expertise, Chroma is well-positioned to continue their pioneering work in the field of genomic medicine and bring hope to patients in need of innovative treatments.
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
- Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
- Fully Accountable Introduces Interactive Accounting Scorecard to Improve Financial Performance
- Pyro Marketing Opens New Digital Marketing Company in Saint Petersburg to Power Growth for Fitness and Ecommerce Brands
- Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
- Warren County Park District Unveils Bold Strategic Plan to Shape Future of Parks and Green Spaces
- Huntington Bancshares Incorporated Announces Second Quarter 2025 Earnings Call Details
- Ringside Talent Provides Finance & Accounting Recruiting to Help Companies Build Strong Teams
- ULGSO Hosts The 2025 Urban Champions Youth Summit: "Lead the Way, Don't Be Led Away"
- $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
- Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
- Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
- Miami Real Estate Agent Drastically Increases Interest In Homes
- Adostics & Genmega Announce the Introduction of A-POD
- Northwest Bancshares, Inc. Announces Second Quarter 2025 Earnings Call Details
- LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
- Heritage at South Brunswick Offers Immediate Townhome Appointments and Special Mortgage Incentive Fast-Moving Sales
- NASA Collaborative Agreement for Supply of Thin-Film Solar Tech for Orbital Application to Advance Development of Thin-Film PV Power Beaming: $ASTI
- Exciting New Era of Sports, Entertainment & Gaming Innovation Spotlighted by Rebrand of Expanding AI Driven, Online Fan Engagement Company: SEGG Media
- Service Ninjas Debuts First-of-Its-Kind "Membership" Platform for Home Service Pros